Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback